Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Insulin degludec is a new-generation basal insulin with an ultra-long duration of action. We evaluated the pharmacokinetic properties of insulin degludec in subjects with normal renal function; mild, moderate or severe renal impairment; or end-stage renal disease (ESRD) undergoing hemodialysis. METHODS: Thirty subjects (n = 6 per group) received a single subcutaneous dose of 0.4 U/kg insulin degludec. Blood samples up to 120 h post-dose and fractionated urine samples were collected. RESULTS: The ultra-long pharmacokinetic properties of insulin degludec were preserved in subjects with renal impairment, with no statistically significant differences in absorption or clearance, compared with subjects with normal renal function. In subjects with ESRD, pharmacokinetic parameters were similar whether the insulin degludec pharmacokinetic assessment period included hemodialysis or not, and total exposure was comparable to subjects with normal renal function. Simulated mean steady-state pharmacokinetic profiles were comparable between groups. CONCLUSION: This study indicated dose adjustments due to impaired renal function should not be required for insulin degludec.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Simulated mean SS profiles demonstrated an even distribution of exposure to IDeg across a 24-h dosing interval, regardless of renal or hepatic function status, indicating that the pharmacokinetic properties observed in patients with normal renal or hepatic function are preserved in patients with impaired renal or hepatic function [27, 28].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Serum, urine and dialysate (where relevant) concentrations of IDeg were measured using a specific sandwich enzyme-linked immunosorbent assay [21, 22, 27, 28].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“Haemodialysis did not affect the pharmacokinetic profile of IDeg in subjects with end-stage renal disease (ESRD) undergoing haemodialysis.”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“This finding is further corroborated in a SD, open-label, parallel-group trial that demonstrated the pharmacokinetic characteristics of IDeg are preserved in adult subjects with different degrees of renal impairment [28].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“Total exposure and C max of IDeg, as well as the apparent total clearance from plasma after SC administration (CL/F) of IDeg were comparable in subjects with normal and varying degrees of impaired renal function (Table 3).”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [28]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Temporal trends in the prevalence of diabetic kidney disease in the United States
de Boer, I. H. (2011) · JAMA · doi:10.1001/jama.2011.861 · Cited by 1,036 · cited 1×
“Impaired renal function is an increasingly common longterm complication of diabetes mellitus [1, 2].”
BackgroundDesign of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448 · cited 1×
“Upon subcutaneous injection, insulin degludec forms long chains of multi-hexamers, resulting in a soluble depot in the subcutaneous tissue from which insulin degludec monomers gradually separate [21, 22].”
BackgroundFrequency of hypoglycemia and its significance in chronic kidney disease
Moen, M. F., Zhan, M., Hsu, V. D., Walker, L. D., Einhorn, L. M., Seliger, S. L., & Fink, J. C. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00800209 · Cited by 423 · cited 2×
“As exogenous insulin is primarily cleared via renal metabolism [1, 7–9], impaired renal function in patients with diabetes can result in decreased clearance of insulin”
BackgroundHeller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., Renard, E., Russell-Jones, D., Philotheou, A., Francisco, A. M. O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60204-9 · Cited by 402
Heise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397 · cited 1×
“lowering effect [23], with a four-times lower within-subject variability in glucose-lowering effect [area under the curve (AUC) values] than insulin glargine [24].”
BackgroundSelf-citationRatner, R. E., Gough, S. C. L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12032 · Cited by 346 · cited 1×
“These properties of insulin degludec lead to a decreased risk of hypoglycemia compared with insulin glargine [24–28].”
BackgroundUltra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes
Heise, T., Nosek, L., Bøttcher, S. G., Hastrup, H., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01638.x · Cited by 331 · cited 3×
“For the assay, the capture antibody was a mouse monoclonal antibody specific for human insulin (HUI 001) and the detection antibody was a biotin-labelled monoclonal mouse antibody (NN454-1 F31) [23].”
BackgroundMethodSelf-citationGarber, A. J., King, A. B., Prato, S. D., Sreenan, S., Balci, M. K., Muñoz-Torres, M., Rosenstock, J., Endahl, L. A., Francisco, A. M. O., & Hollander, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60205-0 · Cited by 325
Snyder, R. W., & Berns, J. S. (2004) · Seminars in Dialysis · doi:10.1111/j.0894-0959.2004.17346.x · Cited by 215
The unrecognized prevalence of chronic kidney disease in diabetes
Middleton, R. J., Foley, R. N., Hegarty, J., Cheung, C. M., McElduff, P., Gibson, J. M., Kalra, P. A., O'Donoghue, D. J., & New, J. P. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi163 · Cited by 169 · cited 1×
“Prevalence rates of co-morbid chronic kidney disease are approximately 30 % in subjects with diabetes [3–5], and type 2 diabetes has now been identified as the most common cause of end-stage renal disease (ESRD) [6].”
BackgroundInsulin Degludec in Type 1 Diabetes
Birkeland, K. I., Home, P. D., Wendisch, U., Ratner, R. E., Johansen, T., Endahl, L. A., Lyby, K., Jendle, J. H., Roberts, A. P., DeVries, J. H., et al. (2011) · Diabetes Care · doi:10.2337/dc10-1925 · Cited by 160
Biesenbach, G., Raml, A., Schmekal, B., & Eichbauer‐Sturm, G. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01025.x · Cited by 140 · cited 1×
“As exogenous insulin is primarily cleared via renal metabolism [1, 7–9], impaired renal function in patients with diabetes can result in decreased clearance of insulin and, consequently, prolonged exposure [10].”
BackgroundInsulin therapy in renal disease
Iglesias, P., & Díez, J. J. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00802.x · Cited by 110 · cited 2×
“Renal impairment is known to affect insulin clearance [7]; however, the effects of renal impairment on the pharmacokinetics of individual insulin products vary.”
BackgroundNew, J. P., Middleton, R., Klebe, B., Farmer, C., de Lusignan, S., Stevens, P. E., & O'Donoghue, D. J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02075.x · Cited by 104 · cited 1×
“Prevalence rates of co-morbid chronic kidney disease are approximately 30 % in subjects with diabetes [3–5], and type 2 diabetes has now been identified as the most common cause of end-stage renal disease (ESRD) [6].”
BackgroundBaldwin, D., Zander, J., Munoz, C., Raghu, P., DeLange-Hudec, S., Lee, H., Emanuele, M. A., Glossop, V., Smallwood, K., & Molitch, M. (2012) · Diabetes Care · doi:10.2337/dc12-0578 · Cited by 103
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
Scheen, A. J. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.777428 · Cited by 91 · cited 2×
“Impairments in renal function in patients with diabetes have been shown to affect the pharmacokinetics of some insulin products [14], including regular human insulin and insulin lispro [15, 16].”
BackgroundRave, K., Heise, T., Pfützner, A., Heinemann, L., & Sawicki, P. T. (2001) · Diabetes Care · doi:10.2337/diacare.24.5.886 · Cited by 89 · cited 1×
“Impairments in renal function in patients with diabetes have been shown to affect the pharmacokinetics of some insulin products [14], including regular human insulin and insulin lispro [15, 16].”
BackgroundPharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment
Holmes, G., Galitz, L., Hu, P., & Lyness, W. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02476.x · Cited by 86 · cited 1×
“However, the pharmacokinetics of other insulin products, including insulin aspart [17, 18] and”
BackgroundDiabetes Management Issues for Patients With Chronic Kidney Disease
Cavanaugh, K. L. (2007) · Clinical Diabetes · doi:10.2337/diaclin.25.3.90 · Cited by 82 · cited 2×
“In addition, deterioration of renal function can lead to increased exposure to insulin therapy, potentially increasing the risk of hypoglycemia and hampering effective diabetes management in these patients [1].”
BackgroundFarrokhi, F., Klindukhova, O., Chandra, P., Peng, L., Smiley, D., Newton, C., Pasquel, F., Fereira, M. E., & Umpierrez, G. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600505 · Cited by 74 · cited 1×
“Diabetes patients with impaired renal function may therefore be at increased risk of hypoglycemia [9, 11–13].”
BackgroundAssogba, G. F. A., Couchoud, C., Roudier, C., Pornet, C., Fosse‐Edorh, S., Romon, I., Druet, C., Stengel, B., & Fagot‐Campagna, A. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.08.004 · Cited by 73
Severe Hypoglycemia in Type I Diabetic Patients With Impaired Kidney Function
Mühlhauser, I., Toth, G., Sawicki, P. T., & Berger, M. (1991) · Diabetes Care · doi:10.2337/diacare.14.4.344 · Cited by 64 · cited 1×
“Diabetes patients with impaired renal function may therefore be at increased risk of hypoglycemia [9, 11–13].”
BackgroundTrends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes
Harvey, J. N. (2003) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200305000-00015 · Cited by 51 · cited 1×
“Prevalence rates of co-morbid chronic kidney disease are approximately 30 % in subjects with diabetes [3–5], and type 2 diabetes has now been identified as the most common cause of end-stage renal disease (ESRD) [6].”
Background
Research works printed but not linked: 3
- Lynes W, Tyler JF, Lawrence A. Renal impairment does not affect insulin aspart pharmacokinetics in type 1 diabetes. Diabetes. 2001;50(suppl 2):A441–2.
- Jacobsen LV, Popescu G, Plum A. Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment. Diabetologia. 2002;45(suppl 1):A259.
- Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia. 2011;54(Suppl 1):S426.
Cited by
A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
Haahr, H., & Heise, T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0165-y · Cited by 226
“trial that demonstrated the pharmacokinetic characteristics of IDeg are preserved in adult subjects with different degrees of renal impairment [28].”
BackgroundMethodResultInfluentialSelf-citationInteractions between kidney disease and diabetes: dangerous liaisons
Pecoits-Filho, R., Abensur, H., Betônico, C. C. R., Machado, A. D., Parente, E. B., Queiroz, M., Salles, J. E. N., Titan, S., & Vencio, S. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0159-z · Cited by 171
“Thus, degludec insulin does not require dose adjustments due to the loss of kidney function [138].”
BackgroundDerivatization with fatty acids in peptide and protein drug discovery
Kurtzhals, P., Østergaard, S., Nishimura, E., & Kjeldsen, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00529-w · Cited by 151
Cyclic Peptide Screening Methods for Preclinical Drug Discovery
Li, X., Craven, T. W., & Levine, P. M. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01077 · Cited by 96
Rosenstock, J., Juneja, R., Beals, J. M., Moyers, J. S., Ilag, L. L., & McCrimmon, R. J. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad037 · Cited by 92
“However, increasing the hydrodynamic size of the insulin, such as insulin peglispro (103), or binding acylated insulins to HSA, such as IDeg (104), can eliminate the need for insulin dose adjustments in diabetes patients with CKD.”
Metadata
- Authors
- Kiss, I., Arold, G., Roepstorff, C., Bøttcher, S. G., Klim, S., & Haahr, H.
- Affiliations
- Szent Imre Egyetemi Oktatókórház (HU)
- PRA Health Sciences (US)
- Novo Nordisk (Denmark) (DK)
- Corresponding author
- Kiss, István
- Venue
- Clinical Pharmacokinetics
- Published
- 2013-10-26
- Volume
- 53
- Issue
- 2
- Pages
- 175-183
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- PMC
- PMC3899495
- OpenAlex
- W2037694686
- Semantic Scholar
- 505604e3a2fdcc5149ff748c3a9db7ec89d57693
- Cited by
- 75
- References
- 27
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 1 · 2020: 9 · 2019: 4 · 2018: 7 · 2017: 5 · 2016: 16 · 2015: 12 · 2014: 4 · 2013: 1
- FWCI
- 8.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Amgen
- Sanofi
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- insulin degludec, pharmacokinetics, renal dysfunction, end-stage renal disease, hemodialysis, basal insulin, ultra-long-acting insulin, dose adjustment, drug clearance, urinary excretion
- MeSH terms
- Aged, Diabetes Mellitus, Type 2, Female, Renal Dialysis, Humans, Hypoglycemic Agents, Kidney, Male, Middle Aged, Dialysis Solutions, Insulin, Long-Acting, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.